Arcutis Biotherapeutics (ARQT) Gross Profit (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Gross Profit of $95.6 million for Q1 2026, up 73.79% year-over-year from $55.0 million in Q1 2025, and down 18.84% quarter-over-quarter from $117.8 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Gross Profit (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Gross Profit history runs 5 years deep, the most recent figure standing at $95.6 million for Q1 2026.
- In Q1 2026, Gross Profit rose 73.79% year-over-year to $95.6 million; the TTM figure through Mar 2026 stood at $378.0 million (up 105.29% YoY), while the FY2025 annual figure was $339.4 million, up 130.22% from the prior year.
- Gross Profit for Q1 2026 stood at $95.6 million, down from $117.8 million in the prior quarter.
- The five-year high for Gross Profit was $117.8 million in Q4 2025, with the low at $456000.0 in Q3 2022.
- The 5-year median for Gross Profit is $39.3 million (2024), against an average of $44.5 million.
- The sharpest annual moves came in 2023 and 2024: Gross Profit soared 7998.03% in 2023, then grew 6.3% in 2024.
- Arcutis Biotherapeutics' Gross Profit stood at $2.5 million in 2022, then soared by 1584.17% to $41.7 million in 2023, then jumped by 49.77% to $62.5 million in 2024, then soared by 88.64% to $117.8 million in 2025, then dropped by 18.84% to $95.6 million in 2026.
- Business Quant data shows ARQT's Gross Profit at $95.6 million in Q1 2026, $117.8 million in Q4 2025, and $90.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 118.92 Mn |
| Jun 30, 2026 | 118.92 Mn |
| Mar 31, 2026 | 95.61 Mn |
| Mar 31, 2026 | 95.61 Mn |
| Dec 31, 2025 | 117.82 Mn |
| Dec 31, 2025 | 117.82 Mn |
| Sep 30, 2025 | 90.53 Mn |
| Sep 30, 2025 | 90.53 Mn |
| Jun 30, 2025 | 74.01 Mn |
| Jun 30, 2025 | 74.01 Mn |
| Mar 31, 2025 | 55.02 Mn |
| Mar 31, 2025 | 55.02 Mn |
| Dec 31, 2024 | 62.46 Mn |
| Dec 31, 2024 | 62.46 Mn |
| Sep 30, 2024 | 39.25 Mn |
| Sep 30, 2024 | 39.25 Mn |
| Jun 30, 2024 | 27.39 Mn |
| Jun 30, 2024 | 27.39 Mn |
| Mar 31, 2024 | 18.31 Mn |
| Mar 31, 2024 | 18.31 Mn |